Trial Profile
Phase I Study to re-Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Multi Dose Regimens to Subjects Sensitised to Birch Pollen.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Stallergenes SA
- 05 May 2009 New trial record